1. Home
  2. INGN vs KZIA Comparison

INGN vs KZIA Comparison

Compare INGN & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inogen Inc

INGN

Inogen Inc

N/A

Current Price

$5.56

Market Cap

177.1M

Sector

Health Care

ML Signal

N/A

Logo Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited

N/A

Current Price

$13.69

Market Cap

154.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
INGN
KZIA
Founded
2001
1994
Country
United States
Australia
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
177.1M
154.5M
IPO Year
2013
2002

Fundamental Metrics

Financial Performance
Metric
INGN
KZIA
Price
$5.56
$13.69
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$11.25
$19.50
AVG Volume (30 Days)
230.4K
182.9K
Earning Date
05-07-2026
06-04-2026
Dividend Yield
N/A
N/A
EPS Growth
43.42
N/A
EPS
N/A
N/A
Revenue
$348,668,000.00
N/A
Revenue This Year
$8.03
N/A
Revenue Next Year
$7.76
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.86
N/A
52 Week Low
$5.34
$4.86
52 Week High
$9.13
$17.40

Technical Indicators

Market Signals
Indicator
INGN
KZIA
Relative Strength Index (RSI) 33.31 50.33
Support Level $5.48 $11.39
Resistance Level $6.73 $14.75
Average True Range (ATR) 0.20 0.96
MACD -0.04 0.01
Stochastic Oscillator 6.48 46.77

Price Performance

Historical Comparison
INGN
KZIA

About INGN Inogen Inc

Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Share on Social Networks: